WO1999029310A3 - Regulation of t cell-mediated immunity by tryptophan and its analogs - Google Patents
Regulation of t cell-mediated immunity by tryptophan and its analogs Download PDFInfo
- Publication number
- WO1999029310A3 WO1999029310A3 PCT/US1998/025840 US9825840W WO9929310A3 WO 1999029310 A3 WO1999029310 A3 WO 1999029310A3 US 9825840 W US9825840 W US 9825840W WO 9929310 A3 WO9929310 A3 WO 9929310A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- tryptophan
- ido
- concentration
- increasing
- regulation
- Prior art date
Links
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 title abstract 13
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 title abstract 10
- 230000026095 regulation of T cell mediated immunity Effects 0.000 title 1
- 229960004799 tryptophan Drugs 0.000 abstract 9
- 102000006639 indoleamine 2,3-dioxygenase Human genes 0.000 abstract 7
- 108020004201 indoleamine 2,3-dioxygenase Proteins 0.000 abstract 7
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 4
- 239000003112 inhibitor Substances 0.000 abstract 3
- ZADWXFSZEAPBJS-UHFFFAOYSA-N 1-methyltryptophan Chemical group C1=CC=C2N(C)C=C(CC(N)C(O)=O)C2=C1 ZADWXFSZEAPBJS-UHFFFAOYSA-N 0.000 abstract 2
- 102000004127 Cytokines Human genes 0.000 abstract 2
- 108090000695 Cytokines Proteins 0.000 abstract 2
- 230000006044 T cell activation Effects 0.000 abstract 2
- 230000033228 biological regulation Effects 0.000 abstract 2
- 230000015556 catabolic process Effects 0.000 abstract 2
- 230000003247 decreasing effect Effects 0.000 abstract 2
- 238000006731 degradation reaction Methods 0.000 abstract 2
- 230000000694 effects Effects 0.000 abstract 2
- 210000002540 macrophage Anatomy 0.000 abstract 2
- 230000035935 pregnancy Effects 0.000 abstract 2
- 230000001629 suppression Effects 0.000 abstract 2
- AWLWPSSHYJQPCH-VIFPVBQESA-N (2s)-2-amino-3-(6-nitro-1h-indol-3-yl)propanoic acid Chemical compound [O-][N+](=O)C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 AWLWPSSHYJQPCH-VIFPVBQESA-N 0.000 abstract 1
- IIQKYWMOMQWBER-UHFFFAOYSA-N 2-amino-3-(1-benzofuran-3-yl)propanoic acid Chemical compound C1=CC=C2C(CC(N)C(O)=O)=COC2=C1 IIQKYWMOMQWBER-UHFFFAOYSA-N 0.000 abstract 1
- GAUUPDQWKHTCAX-UHFFFAOYSA-N 2-azaniumyl-3-(1-benzothiophen-3-yl)propanoate Chemical compound C1=CC=C2C(CC(N)C(O)=O)=CSC2=C1 GAUUPDQWKHTCAX-UHFFFAOYSA-N 0.000 abstract 1
- 102000004190 Enzymes Human genes 0.000 abstract 1
- 108090000790 Enzymes Proteins 0.000 abstract 1
- 102000008070 Interferon-gamma Human genes 0.000 abstract 1
- 108010074328 Interferon-gamma Proteins 0.000 abstract 1
- 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 abstract 1
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 241000700605 Viruses Species 0.000 abstract 1
- 230000000735 allogeneic effect Effects 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000000593 degrading effect Effects 0.000 abstract 1
- 230000008030 elimination Effects 0.000 abstract 1
- 238000003379 elimination reaction Methods 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 229960003130 interferon gamma Drugs 0.000 abstract 1
- 230000036210 malignancy Effects 0.000 abstract 1
- 239000003550 marker Substances 0.000 abstract 1
- 230000001502 supplementing effect Effects 0.000 abstract 1
- 238000002054 transplantation Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New breeds of animals
- A01K67/027—New breeds of vertebrates
- A01K67/0271—Chimeric animals, e.g. comprising exogenous cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Abstract
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU16285/99A AU1628599A (en) | 1997-12-05 | 1998-12-04 | Regulation of t cell-mediated immunity by tryptophan |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US6761097P | 1997-12-05 | 1997-12-05 | |
US60/067,610 | 1997-12-05 | ||
US8038498P | 1998-04-01 | 1998-04-01 | |
US8038098P | 1998-04-01 | 1998-04-01 | |
US60/080,380 | 1998-04-01 | ||
US60/080,384 | 1998-04-01 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO1999029310A2 WO1999029310A2 (en) | 1999-06-17 |
WO1999029310A3 true WO1999029310A3 (en) | 2000-01-06 |
Family
ID=27371203
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1998/025841 WO1999029852A1 (en) | 1997-12-05 | 1998-12-04 | High-affinity tryptophan transporter |
PCT/US1998/025840 WO1999029310A2 (en) | 1997-12-05 | 1998-12-04 | Regulation of t cell-mediated immunity by tryptophan and its analogs |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1998/025841 WO1999029852A1 (en) | 1997-12-05 | 1998-12-04 | High-affinity tryptophan transporter |
Country Status (3)
Country | Link |
---|---|
US (7) | US6451840B1 (en) |
AU (2) | AU1628599A (en) |
WO (2) | WO1999029852A1 (en) |
Families Citing this family (73)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999029852A1 (en) * | 1997-12-05 | 1999-06-17 | Medical College Of Georgia Research Institute, Inc. | High-affinity tryptophan transporter |
DK0951842T3 (en) * | 1999-01-20 | 2003-01-06 | Nutricia Nv | Nutritional product for an infant |
EP1185687A1 (en) * | 1999-05-03 | 2002-03-13 | Ludwig Institute For Cancer Research | Methods for increasing t cell proliferation |
US20030139361A1 (en) * | 2000-01-21 | 2003-07-24 | Kazuhiro Yuda | Drug for gene therapy |
US20060292618A1 (en) * | 2002-04-12 | 2006-12-28 | Mellor Andrew L | Antigen-presenting cell populations and their use as reagents for enhancing or reducing immune tolerance |
AU2002307243B2 (en) * | 2002-04-12 | 2008-01-03 | Medical College Of Georgia Research Institute, Inc. | Antigen-presenting cell populations and their use as reagents for enhancing or reducing immune tolerance |
EP1527338B1 (en) * | 2002-07-26 | 2011-08-31 | Instrumentation Laboratory Company | Method for reducing the rate of oxygen loss from aqueous solutions |
AU2003267088A1 (en) * | 2002-09-11 | 2004-04-30 | Medical College Of Georgia Research Institute, Inc. | Chemokine receptor antagonists as therapeutic agents |
US9388427B2 (en) | 2002-12-02 | 2016-07-12 | Biovec, Llc | In vivo and ex vivo gene transfer into renal tissue using gutless adenovirus vectors |
US7422903B2 (en) * | 2002-12-11 | 2008-09-09 | Instrumentation Laboratory Company | Multi-analyte reference solutions |
US20040154933A1 (en) * | 2003-02-11 | 2004-08-12 | Instrumentation Laboratory Company | Polymeric membranes for use in electrochemical sensors |
US20040256227A1 (en) * | 2003-02-11 | 2004-12-23 | Jungwon Shin | Electrochemical urea sensors and methods of making the same |
US8008281B2 (en) | 2003-03-27 | 2011-08-30 | Lankenau Institute For Medical Research | Methods for the treatment of cancer |
US7598287B2 (en) | 2003-04-01 | 2009-10-06 | Medical College Of Georgia Research Institute, Inc. | Use of inhibitors of indoleamine-2,3-dioxygenase in combination with other therapeutic modalities |
US20050186289A1 (en) * | 2003-04-01 | 2005-08-25 | Medical College Of Georgia Research Institute, Inc. | Regulation of T cell-mediated immunity by D isomers of inhibitors of indoleamine-2,3-dioxygenase |
CA2581674A1 (en) * | 2004-07-13 | 2006-01-19 | The University Of British Columbia | Indoleamine 2,3-dioxygenase (ido) inhibitors |
NZ562919A (en) | 2005-05-10 | 2011-04-29 | Incyte Corp | 1,2,5-Oxadiazole-3-carboximidamide derivatives for the treatment of cancer |
EP1926813B2 (en) | 2005-09-23 | 2019-05-22 | TiGenix, S.A.U. | Cell populations having immunoregulatory activity, method for isolation and uses |
EP1937303A4 (en) * | 2005-10-21 | 2009-11-18 | Med College Georgia Res Inst | The induction of indoleamine 2,3-dioxygenase in dendritic cells by tlr ligands and uses thereof |
CA2634198C (en) | 2005-12-20 | 2014-06-03 | Incyte Corporation | N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase |
US20090155311A1 (en) * | 2006-01-07 | 2009-06-18 | Med. College Of Georgia Research Institute, Inc. | Indoleamine 2,3-dioxygenase pathways in the generation of regulatory t cells |
CL2007002650A1 (en) | 2006-09-19 | 2008-02-08 | Incyte Corp | COMPOUNDS DERIVED FROM HETEROCICLO N-HIDROXIAMINO; PHARMACEUTICAL COMPOSITION, USEFUL TO TREAT CANCER, VIRAL INFECTIONS AND NEURODEGENERATIVE DISORDERS BETWEEN OTHERS. |
ES2444574T3 (en) | 2006-09-19 | 2014-02-25 | Incyte Corporation | N-hydroxyamidinoheterocycles as modulators of indolamine 2,3-dioxygenase |
CN101932325B (en) * | 2007-11-30 | 2014-05-28 | 新联基因公司 | Ido inhibitors |
PL2280721T3 (en) | 2008-04-17 | 2018-04-30 | Io Biotech Aps | Indoleamine 2, 3-dioxygenase based immunotherapy |
TWI453204B (en) | 2008-07-08 | 2014-09-21 | Incyte Corp | 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase |
GB0820397D0 (en) * | 2008-11-07 | 2008-12-17 | Cellerix Sa | Cells, nucleic acid constructs, cells comprising said constructs and methods utilizing said cells in the treatment of diseases |
US8722720B2 (en) | 2009-10-28 | 2014-05-13 | Newlink Genetics Corporation | Imidazole derivatives as IDO inhibitors |
CA2788284A1 (en) * | 2010-02-09 | 2011-08-18 | Georgia Health Sciences University Research Institute, Inc. | Alpha-methyl-tryptophan as an inhibitor of indoleamine dioxygenase |
NO2694640T3 (en) | 2011-04-15 | 2018-03-17 | ||
WO2013040552A2 (en) | 2011-09-16 | 2013-03-21 | Georgia Health Sciences University | Methods of promoting immune tolerance |
DE102011085695A1 (en) | 2011-11-03 | 2013-05-08 | Jörg Pohl | One-time dosed oxazaphosphorines for the treatment of diseases |
GB201120860D0 (en) | 2011-12-05 | 2012-01-18 | Cambridge Entpr Ltd | Cancer immunotherapy |
US10034939B2 (en) | 2012-10-26 | 2018-07-31 | The University Of Chicago | Synergistic combination of immunologic inhibitors for the treatment of cancer |
CN104884452A (en) | 2012-11-20 | 2015-09-02 | 沃泰克斯药物股份有限公司 | Compounds useful as inhibitors of indoleamine 2,3-dioxygenase |
JP6093903B2 (en) | 2013-03-14 | 2017-03-08 | ニューリンク ジェネティクス コーポレイション | Inhibitors of immunosuppression mediated by tryptophan metabolism |
ES2799582T3 (en) | 2013-11-08 | 2020-12-18 | Incyte Holdings Corp | Process for the synthesis of an indoleamine 2,3-dioxygenase inhibitor |
BR112016028255A2 (en) | 2014-06-06 | 2017-08-22 | Flexus Biosciences Inc | immunoregulatory agents |
UY36390A (en) | 2014-11-05 | 2016-06-01 | Flexus Biosciences Inc | MODULATING COMPOUNDS OF INDOLAMINE ENZYME 2,3-DIOXYGENASE (IDO), ITS SYNTHESIS METHODS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM |
CN107205970A (en) | 2014-11-05 | 2017-09-26 | 弗莱塞斯生物科学公司 | Immunomodulator |
AR102537A1 (en) | 2014-11-05 | 2017-03-08 | Flexus Biosciences Inc | IMMUNOMODULATING AGENTS |
US20180271861A1 (en) | 2015-07-14 | 2018-09-27 | Kyowa Hakko Kirin Co., Ltd. | Therapeutic agent for a tumor comprising an ido inhibitor administered in combination with an antibody |
CR20180023A (en) | 2015-07-24 | 2018-03-20 | Newlink Genetics Corp | SALTS AND PROPHARMACES OF 1-METHYL-D-TRIPTOPHAN |
WO2017044979A2 (en) * | 2015-09-11 | 2017-03-16 | Ventria Bioscience Inc. | Lactoferrin compositions and methods for modulation of t cell subtypes and treatment of autoimmune diseases |
EP3370699A1 (en) | 2015-11-04 | 2018-09-12 | Incyte Corporation | Pharmaceutical compositions and methods for indoleamine 2,3-dioxygenase inhibition and indications therefor |
WO2017106062A1 (en) | 2015-12-15 | 2017-06-22 | Merck Sharp & Dohme Corp. | Novel compounds as indoleamine 2,3-dioxygenase inhibitors |
US10800780B2 (en) | 2015-12-24 | 2020-10-13 | Genentech, Inc. | TDO2 Inhibitors |
US10494360B2 (en) | 2016-03-09 | 2019-12-03 | Netherlands Translational Research Center B.V | Inhibitors of indoleamine 2,3-dioxygenase |
CN109328232A (en) * | 2016-04-12 | 2019-02-12 | 辛普洛德生物技术有限责任公司 | For generating the method and application thereof of the synthesis chromosome of expression biosynthesis pathway |
KR20190003685A (en) | 2016-05-04 | 2019-01-09 | 브리스톨-마이어스 스큅 컴퍼니 | Inhibitors of indoleamine 2,3-dioxygenase and methods of use thereof |
KR20190003687A (en) | 2016-05-04 | 2019-01-09 | 브리스톨-마이어스 스큅 컴퍼니 | Inhibitors of indoleamine 2,3-dioxygenase and methods of use thereof |
EP3452029A4 (en) | 2016-05-04 | 2019-10-30 | Bristol-Myers Squibb Company | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use |
US11066383B2 (en) | 2016-05-04 | 2021-07-20 | Bristol-Myers Squibb Company | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use |
EP3452452A4 (en) | 2016-05-04 | 2019-10-30 | Bristol-Myers Squibb Company | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use |
JP2019528301A (en) | 2016-08-26 | 2019-10-10 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | Indoleamine 2,3-dioxygenase inhibitors and methods of use thereof |
CN109843322A (en) | 2016-08-26 | 2019-06-04 | 百时美施贵宝公司 | The inhibitor and its application method of indole amine 2,3-dioxygenase |
WO2018054365A1 (en) | 2016-09-24 | 2018-03-29 | Beigene, Ltd. | NOVEL 5 or 8-SUBSTITUTED IMIDAZO [1, 5-a] PYRIDINES AS SELECTIVE INHIBITORS OF INDOLEAMINE AND/OR TRYPTOPHANE 2, 3-DIOXYGENASES |
WO2018175954A1 (en) | 2017-03-23 | 2018-09-27 | F. Hoffmann-La Roche Ag | Synthesis of imidazo[5,1-a]isoindole derivative useful as ido inhibitors |
WO2018196747A1 (en) | 2017-04-24 | 2018-11-01 | 南京药捷安康生物科技有限公司 | Indoleamine 2,3-dioxygenase inhibitor and application |
CA3061340A1 (en) | 2017-04-25 | 2018-11-01 | Temple Otorongo Llc | Pharmaceutical composition comprising tryptophan and phyllokinin derivative for use in treating psychiatric and psychological conditions |
WO2018209049A1 (en) | 2017-05-12 | 2018-11-15 | Bristol-Myers Squibb Company | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use |
EP3645533A1 (en) | 2017-06-28 | 2020-05-06 | Genentech, Inc. | Tdo2 and ido1 inhibitors |
US11827639B2 (en) | 2017-06-28 | 2023-11-28 | Genentech, Inc. | TDO2 and IDO1 inhibitors |
WO2019043103A1 (en) | 2017-09-01 | 2019-03-07 | Netherlands Translational Research Center B.V. | 3-hydroxy-imidazolidin-4-one compounds as inhibitors of indoleamine 2,3-dioxygenase |
WO2019074824A1 (en) | 2017-10-09 | 2019-04-18 | Bristol-Myers Squibb Company | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use |
US11649212B2 (en) | 2017-10-09 | 2023-05-16 | Bristol-Myers Squibb Company | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use |
WO2019136112A1 (en) | 2018-01-05 | 2019-07-11 | Bristol-Myers Squibb Company | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use |
US20190314324A1 (en) | 2018-04-13 | 2019-10-17 | The University Of Chicago | Combination of micheliolide derivatives or nanoparticles with ionizing radiation and checkpoint inhibitors for cancer therapy |
GB201809050D0 (en) | 2018-06-01 | 2018-07-18 | E Therapeutics Plc | Modulators of tryptophan catabolism |
US20210299126A1 (en) | 2018-07-23 | 2021-09-30 | Bristol-Myers Squibb Company | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use |
US20210355113A1 (en) | 2018-07-23 | 2021-11-18 | Bristol-Myers Squibb Company | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use |
US20210403602A1 (en) | 2018-12-03 | 2021-12-30 | Bristol-Myers Squibb Company | Anti-ido antibody and uses thereof |
CN112807296B (en) * | 2021-02-10 | 2022-06-28 | 上海市第一妇婴保健院 | Use of succinic acid for diagnosis or treatment of spontaneous abortion |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0385385A2 (en) * | 1989-02-28 | 1990-09-05 | Morinaga Milk Industry Co., Ltd. | Human monocyte-machrophage-CSF preparations |
Family Cites Families (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4244946A (en) | 1979-06-11 | 1981-01-13 | The Salk Institute For Biological Studies | Water-soluble peptides affecting gonadal function |
US4305872A (en) | 1979-10-19 | 1981-12-15 | Kenneth Wingrove | Polypeptide derivatives |
US4316891A (en) | 1980-06-14 | 1982-02-23 | The Salk Institute For Biological Studies | Extended N-terminal somatostatin |
US4792525A (en) | 1982-08-04 | 1988-12-20 | La Jolla Cancer Research Foundation | Tetrapeptide |
US4629784A (en) | 1983-08-16 | 1986-12-16 | The University Of Georgia Research Foundation, Inc. | Synthesis of cyclopropane amino acids |
AU6131086A (en) | 1985-07-05 | 1987-01-30 | Whitehead Institute For Biomedical Research | Epithelial cells expressing foreign genetic material |
US4980286A (en) | 1985-07-05 | 1990-12-25 | Whitehead Institute For Biomedical Research | In vivo introduction and expression of foreign genetic material in epithelial cells |
US5244807A (en) | 1990-05-23 | 1993-09-14 | Automedix Sciences, Inc. | Production of pseudomonas xa cells containing indolyl-3-alkane alpha-hydroxylase |
US5273889A (en) * | 1990-08-22 | 1993-12-28 | University Of Saskatchewan | Gamma-iterferon-leukotoxin gene fusions and uses thereof |
AU659482B2 (en) | 1991-06-28 | 1995-05-18 | Massachusetts Institute Of Technology | Localized oligonucleotide therapy |
US5185376A (en) * | 1991-09-24 | 1993-02-09 | The United States Of America As Represented By The Department Of Health And Human Services | Therapeutic inhibition of platelet aggregation by nucleophile-nitric oxide complexes and derivatives thereof |
US5234696A (en) * | 1991-12-27 | 1993-08-10 | Abbott Laboratories | Method of producing tablets, tablets produced thereby, and method of treatment using same |
EP0741580A4 (en) | 1993-12-14 | 2001-07-11 | Univ Johns Hopkins Med | Controlled release of pharmaceutically active substances for immunotherapy |
US5478556A (en) | 1994-02-28 | 1995-12-26 | Elliott; Robert L. | Vaccination of cancer patients using tumor-associated antigens mixed with interleukin-2 and granulocyte-macrophage colony stimulating factor |
US5874560A (en) * | 1994-04-22 | 1999-02-23 | The United States Of America As Represented By The Department Of Health And Human Services | Melanoma antigens and their use in diagnostic and therapeutic methods |
US6509313B1 (en) * | 1996-02-28 | 2003-01-21 | Cornell Research Foundation, Inc. | Stimulation of immune response with low doses of cytokines |
US5837231A (en) | 1996-06-27 | 1998-11-17 | Regents Of The University Of Minnesota | GM-CSF administration for the treatment and prevention of recurrence of brain tumors |
US5879707A (en) | 1996-10-30 | 1999-03-09 | Universite De Montreal | Substituted amylose as a matrix for sustained drug release |
US6074645A (en) | 1996-11-12 | 2000-06-13 | City Of Hope | Immuno-reactive peptide CTL epitopes of human cytomegalovirus |
IT1287582B1 (en) | 1996-12-12 | 1998-08-06 | Ima Spa | CONTAINER TRANSPORT DEVICE, IN PARTICULAR BOTTLES AND BOTTLES, THROUGH DIFFERENT OPERATING STATIONS |
WO1999029852A1 (en) | 1997-12-05 | 1999-06-17 | Medical College Of Georgia Research Institute, Inc. | High-affinity tryptophan transporter |
AU776150B2 (en) | 1999-01-28 | 2004-08-26 | Medical College Of Georgia Research Institute, Inc. | Composition and method for (in vivo) and (in vitro) attenuation of gene expression using double stranded RNA |
EP1185687A1 (en) | 1999-05-03 | 2002-03-13 | Ludwig Institute For Cancer Research | Methods for increasing t cell proliferation |
AU2002307243B2 (en) * | 2002-04-12 | 2008-01-03 | Medical College Of Georgia Research Institute, Inc. | Antigen-presenting cell populations and their use as reagents for enhancing or reducing immune tolerance |
US20060292618A1 (en) * | 2002-04-12 | 2006-12-28 | Mellor Andrew L | Antigen-presenting cell populations and their use as reagents for enhancing or reducing immune tolerance |
AU2003267088A1 (en) | 2002-09-11 | 2004-04-30 | Medical College Of Georgia Research Institute, Inc. | Chemokine receptor antagonists as therapeutic agents |
US8008281B2 (en) | 2003-03-27 | 2011-08-30 | Lankenau Institute For Medical Research | Methods for the treatment of cancer |
US7598287B2 (en) * | 2003-04-01 | 2009-10-06 | Medical College Of Georgia Research Institute, Inc. | Use of inhibitors of indoleamine-2,3-dioxygenase in combination with other therapeutic modalities |
US20050186289A1 (en) * | 2003-04-01 | 2005-08-25 | Medical College Of Georgia Research Institute, Inc. | Regulation of T cell-mediated immunity by D isomers of inhibitors of indoleamine-2,3-dioxygenase |
WO2006040796A1 (en) | 2004-10-08 | 2006-04-20 | Mitsubishi Denki Kabushiki Kaisha | Communication system and relay apparatus |
EP1739776A1 (en) | 2005-06-28 | 2007-01-03 | Siemens Aktiengesellschaft | Method of feeding operation gases into a gas-inlet cavity of a fuel cell and a fuel cell |
EP1937303A4 (en) * | 2005-10-21 | 2009-11-18 | Med College Georgia Res Inst | The induction of indoleamine 2,3-dioxygenase in dendritic cells by tlr ligands and uses thereof |
US20090155311A1 (en) * | 2006-01-07 | 2009-06-18 | Med. College Of Georgia Research Institute, Inc. | Indoleamine 2,3-dioxygenase pathways in the generation of regulatory t cells |
WO2008100562A2 (en) | 2007-02-14 | 2008-08-21 | Medical College Of Georgia Research Institute, Inc. | Indoleamine 2,3-dioxygenase, pd-1/pd-l pathways, and ctla4 pathways in the activation of regulatory t cells |
-
1998
- 1998-12-04 WO PCT/US1998/025841 patent/WO1999029852A1/en active Application Filing
- 1998-12-04 US US09/206,274 patent/US6451840B1/en not_active Expired - Lifetime
- 1998-12-04 WO PCT/US1998/025840 patent/WO1999029310A2/en active Application Filing
- 1998-12-04 AU AU16285/99A patent/AU1628599A/en not_active Abandoned
- 1998-12-04 US US09/205,939 patent/US6395876B1/en not_active Expired - Lifetime
- 1998-12-04 AU AU16286/99A patent/AU1628699A/en not_active Abandoned
-
2000
- 2000-11-30 US US09/727,055 patent/US6482416B2/en not_active Expired - Lifetime
-
2002
- 2002-03-28 US US10/112,362 patent/US7160539B2/en not_active Expired - Lifetime
-
2006
- 2006-11-21 US US11/602,930 patent/US7879791B2/en not_active Expired - Lifetime
- 2006-11-21 US US11/603,291 patent/US8198265B2/en not_active Expired - Lifetime
-
2012
- 2012-05-21 US US13/476,183 patent/US20120288472A1/en not_active Abandoned
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0385385A2 (en) * | 1989-02-28 | 1990-09-05 | Morinaga Milk Industry Co., Ltd. | Human monocyte-machrophage-CSF preparations |
Non-Patent Citations (11)
Also Published As
Publication number | Publication date |
---|---|
US20010001040A1 (en) | 2001-05-10 |
WO1999029310A2 (en) | 1999-06-17 |
US20070077224A1 (en) | 2007-04-05 |
US8198265B2 (en) | 2012-06-12 |
AU1628699A (en) | 1999-06-28 |
US6395876B1 (en) | 2002-05-28 |
US7879791B2 (en) | 2011-02-01 |
WO1999029852A1 (en) | 1999-06-17 |
US20120288472A1 (en) | 2012-11-15 |
AU1628599A (en) | 1999-06-28 |
US6451840B1 (en) | 2002-09-17 |
US20020155104A1 (en) | 2002-10-24 |
US7160539B2 (en) | 2007-01-09 |
US20070077234A1 (en) | 2007-04-05 |
US6482416B2 (en) | 2002-11-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO1999029310A3 (en) | Regulation of t cell-mediated immunity by tryptophan and its analogs | |
DE59305359D1 (en) | DESODORING COSMETIC PREPARATIONS CONTAINING DI- OR TRIGLYCERINE ESTERS | |
UA26303A1 (en) | PHARMACEUTICAL COMPOSITION WITH IMHUSOSPRESSOR AND ACTIMICROBIAL ACTIVITY | |
ES2038752T3 (en) | PROCEDURE TO PREPARE DISSTITUTED ACETYLENE WITH A PHENYLUS GROUP AND A HETEROBYCLICAL GROUP, WHICH HAVE RETINOID TYPE ACTIVITY. | |
AU2092497A (en) | Nitric oxide donors capable of reducing toxicity from drugs | |
ES2041794T3 (en) | STABILIZED VINYL AROMATIC COMPOSITION. | |
ES2050607A1 (en) | Photopolymerizable compositions containing an alkylbisacylphosphine oxide | |
NO994722D0 (en) | Nutritional formulations containing Lacto-N-neotetraose | |
NO20000314D0 (en) | Pharmaceutical compositions containing lysostaphin alone or in combination with an antibiotic for the treatment of staphylococcal infections | |
ES2051650A1 (en) | Methods for scavenging active oxygen compounds and preventing damage from ultra violet B rays using taurine analogues | |
EP0144986A3 (en) | Indole-3-carboxamide derivatives | |
CO4920220A1 (en) | COMPOSITIONS CONTAINING FLUOROETER COMPOUNDS AND METHODS TO INHIBIT THEIR DEGRADATION IN THE PRESENCE OF A LEWIS ACID | |
GR3036211T3 (en) | Taxane class derivative based pharmaceutical compositions | |
IL127542A0 (en) | Administration regimen of H+ K+ -ATPase inhibitors | |
GB9925955D0 (en) | Hcv n33 protease inhibitors | |
KR950704315A (en) | Substituted Triols | |
AU5699494A (en) | Novel liquid phenolic antioxidants | |
ES2174113T3 (en) | NEW DERIVATIVES OF ((3-ALCOXI-FENOXI) -ETIL) -DIALQUILAMINE AND ITS USE AS LOCAL ANESTHETICS. | |
KR970064396A (en) | Stress Relief Feed | |
ES2184343T3 (en) | PHARMACEUTICAL COMPOSITIONS BASED ON DALFOPRISTIN AND QUINUPRISTINE AND ITS PREPARATION. | |
SE0001071D0 (en) | Method of inhibiting the expression of inflammatory cytokines and chemokines | |
AU558461B2 (en) | Carbamyloxybenzhyrol derivatives | |
AU3027697A (en) | Pharmaceutical compositions containing cyclosporine and a carrier comprising at least an ester of alpha-glycerophosphoric acid | |
KR950002753A (en) | Cartilage protectors | |
JPS6463342A (en) | Stabilization of glutathione-containing composition |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
NENP | Non-entry into the national phase |
Ref country code: KR |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
122 | Ep: pct application non-entry in european phase |